Media Advisory: GenSpera's G-202 HCC Clinical Trial Presentation from 5th Asia-Pacific Primary Liver Cancer Expert (APPLE) Meeting Available

SAN ANTONIO, July 22, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces the Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE) presentation of the G-202 hepatocellular carcinoma (HCC) clinical trial data is now available for download for media and investors.  

On July 12^th  Devalingam Mahalingam, MD, PhD, Principal Investigator of the G-202 Phase II trial in HCC patients, presented the HCC clinical trial update for G-202, in Taipei, Taiwan.

HCC is the sixth most common malignancy worldwide. It is the fifth most common malignant disease in men and the eighth most common in women. It is the third most common cause of death from cancer, after lung and stomach cancer.*

Dr. Craig Dionne, GenSpera CEO, recently said of its lead drug candidate G-202, based on the new data presented, "These positive results enable management to remain optimistic about our ambitious G-202 clinical development program which is expanding into glioblastoma, prostate cancer and renal cell carcinoma trials. Although still in early stages, we believe this clinical strategy will continue to build significant value in G-202 and in the company. We are particularly excited by the potential that G-202 is showing as a treatment for patients with liver cancer, a market which is expected to be at $1.5 billion by 2019."

Presentation

"Clinical Activity of G-202, a Thapsigargin-Based Prostate Specific Membrane Antigen (PSMA)-Activated Prodrug in Patients with Progressive Hepatocellular Carcinoma (HCC)"

Media and investors can view Dr. Mahalingam's presentation at: http://www.genspera.com/press/140712_APPLE2014-mahalingam-oral_FINAL.pdf

About GenSpera

GenSpera's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of drug candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin results in cell death irrespective of the rate of cell division, which may provide an effective approach to kill both fast- and slow-growing cancers. GenSpera's lead drug candidate, G-202, is activated by the enzyme PSMA, which is found at high levels in the vasculature of liver and glioblastoma cancers and in the vasculature of almost all other solid tumors. G-202 is therefore expected to have potential efficacy in a wide variety of tumor types.

G-202 Phase II clinical trials are underway in hepatocellular carcinoma, glioblastoma and prostate cancer patients.

For more information, please visit the company's website: www.genspera.com or follow us on Twitter @GenSperaNews.

*Source: http://www.worldgastroenterology.org/assets/downloads/en/pdf/guidelines/24_hepatocellular_carcinoma_en.pdf

About APPLE 2014

The Asia-Pacific Primary Liver Cancer Expert Association (APPLE) Congress was held July 11 – 13, 2014, at the Grand Hotel Taipei in Taipei, Taiwan. APPLE 2014 is hosted by the Chinese Oncology Society of Taiwan and co-hosted by the Taiwan Association for the Study of the Liver, the Gastroenterological Society of Taiwan, and the Taiwan Liver Cancer Association. APPLE is an international platform for HCC that brings together scientific experts from across the world to discuss curative treatment, systemic and anti-viral therapies, HCC pathology and social perspectives as well. http://www.2014applecongress.org.

Cautionary Statement Regarding Forward Looking Information

This news release may contain forward-looking statements. Investors are cautioned that statements in this press release regarding potential applications of GenSpera's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties will be detailed from time to time in GenSpera's periodic reports filed with the Securities and Exchange Commission.

CONTACT: 

Company:  
Craig Dionne, PhD, CEO
GenSpera, Inc. 
+1-210-479-8112                                     

Investors:   
Steve Gersten
Capital Markets Group
[email protected]
+1-813-926-8920

Media:       
D. Van Zant
800-665-0411

SOURCE GenSpera, Inc.